Paper33972740
RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor.
Chen Y and 6 others. Cell Mol Immunol, 2021. Cited by 124 papers, by iCite.
Cite this record
ConductScience Library. RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor. Papers, record 33972740. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33972740
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Azetidines | Major topic |
| Inflammation | Major topic |
| NLR Family, Pyrin Domain-Containing 3 Protein | Major topic |
| Nitro Compounds | Major topic |
| Animals | |
| CARD Signaling Adaptor Proteins | |
| Colitis | |
| Cysteine | |
| Dextran Sulfate | |
| Encephalomyelitis, Autoimmune, Experimental | |
| Inflammasomes | |
| Lipopolysaccharides | |
| Macrophages | |
| Mice, Inbred C57BL | |
| NIMA-Related Kinases | |
| Protein Domains | |
| Mice |
Source PubMed
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19302040 | The inflammasomes: guardians of the body. | Annu Rev Immunol | 2009 | https://conductscience.org/library/papers/19302040 | PubMed |
| 2 | 21219188 | The inflammasome NLRs in immunity, inflammation, and associated diseases. | Annu Rev Immunol | 2011 | https://conductscience.org/library/papers/21219188 | PubMed |
| 3 | 27291964 | Inflammasomes: mechanism of assembly, regulation and signalling. | Nat Rev Immunol | 2016 | https://conductscience.org/library/papers/27291964 | PubMed |
| 4 | 16407889 | Gout-associated uric acid crystals activate the NALP3 inflammasome. | Nature | 2006 | https://conductscience.org/library/papers/16407889 | PubMed |
| 5 | 20835230 | Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. | Nat Immunol | 2010 | https://conductscience.org/library/papers/20835230 | PubMed |
| 6 | 21478880 | Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. | Nat Immunol | 2011 | https://conductscience.org/library/papers/21478880 | PubMed |
| 7 | 23254930 | NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. | Nature | 2013 | https://conductscience.org/library/papers/23254930 | PubMed |
| 8 | 20428172 | NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. | Nature | 2010 | https://conductscience.org/library/papers/20428172 | PubMed |
| 9 | 20442201 | Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. | Gut | 2010 | https://conductscience.org/library/papers/20442201 | PubMed |
| 10 | 20303296 | The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. | Immunity | 2010 | https://conductscience.org/library/papers/20303296 | PubMed |
| 11 | 22974247 | Inflammasomes and their roles in health and disease. | Annu Rev Cell Dev Biol | 2012 | https://conductscience.org/library/papers/22974247 | PubMed |
| 12 | 24265316 | 3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. | J Biol Chem | 2014 | https://conductscience.org/library/papers/24265316 | PubMed |
| 13 | 25686105 | A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. | Nat Med | 2015 | https://conductscience.org/library/papers/25686105 | PubMed |
| 14 | 29021150 | Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. | J Exp Med | 2017 | https://conductscience.org/library/papers/29021150 | PubMed |
| 15 | 29959312 | Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. | Nat Commun | 2018 | https://conductscience.org/library/papers/29959312 | PubMed |
| 16 | 29378952 | OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. | Proc Natl Acad Sci U S A | 2018 | https://conductscience.org/library/papers/29378952 | PubMed |
| 17 | 31086327 | MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. | Nat Chem Biol | 2019 | https://conductscience.org/library/papers/31086327 | PubMed |
| 18 | 33005902 | Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. | Lancet Rheumatol | 2020 | https://conductscience.org/library/papers/33005902 | PubMed |
| 19 | 27084426 | Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial. | Transl Oncol | 2016 | https://conductscience.org/library/papers/27084426 | PubMed |
| 20 | 31231122 | RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. | Br J Cancer | 2019 | https://conductscience.org/library/papers/31231122 | PubMed |
Cited by76
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 124 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42272621 | Progress in the Treatment of Ulcerative Colitis by Targeting NLRP3 Inflammasome. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42272621 | PubMed |
| 42154002 | Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42154002 | PubMed |
| 42039709 | High-Throughput Screening Reveals That CeeNU Acts as a New NLRP3 Inflammasome Inhibitor. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42039709 | PubMed |
| 41843135 | ML364 ameliorates NLRP3-induced inflammatory response. | Inflamm Res | 2026 | https://conductscience.org/library/papers/41843135 | PubMed |
| 41231359 | ML345 is a potent and selective NLRP3 inflammasome inhibitor with anti-inflammatory activity. | Mol Biomed | 2025 | https://conductscience.org/library/papers/41231359 | PubMed |
| 40642495 | Immune cell metabolism in cancer drug resistance: Advances in target discovery and clinical translation. | Chin J Cancer Res | 2025 | https://conductscience.org/library/papers/40642495 | PubMed |
| 40492417 | Pinosylvin Inhibits Inflammatory and Osteoclastogenesis via NLRP3 Inflammasome. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40492417 | PubMed |
| 40425567 | Clustering of NLRP3 induced by membrane or protein scaffolds promotes inflammasome assembly. | Nat Commun | 2025 | https://conductscience.org/library/papers/40425567 | PubMed |
| 40374417 | Targeting the NLRP3 inflammasome for inflammatory disease therapy. | Trends Pharmacol Sci | 2025 | https://conductscience.org/library/papers/40374417 | PubMed |
| 40372511 | Targeting cholesterol-driven pyroptosis: a promising strategy for the prevention and treatment of atherosclerosis. | Mol Biol Rep | 2025 | https://conductscience.org/library/papers/40372511 | PubMed |
| 40370770 | Pharmacologic Targeting of PDIA1 Inhibits NLRP3 Inflammasome Assembly and Activation. | Isr J Chem | 2024 | https://conductscience.org/library/papers/40370770 | PubMed |
| 40326096 | NLRP3 Inflammasome in Vascular Dementia: Regulatory Mechanisms, Functions, and Therapeutic Implications: A Comprehensive Review. | CNS Neurosci Ther | 2025 | https://conductscience.org/library/papers/40326096 | PubMed |
| 40307577 | Updated insights into the molecular networks for NLRP3 inflammasome activation. | Cell Mol Immunol | 2025 | https://conductscience.org/library/papers/40307577 | PubMed |
| 40185713 | A small molecule directly targets NLRP3 to promote inflammasome activation and antitumor immunity. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/40185713 | PubMed |
| 40100493 | New Insights on the Potential Role of Pyroptosis in Parkinson's Neuropathology and Therapeutic Targeting of NLRP3 Inflammasome with Recent Advances in Nanoparticle-Based miRNA Therapeutics. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/40100493 | PubMed |
| 39979245 | Lactylation in cancer: metabolic mechanism and therapeutic strategies. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/39979245 | PubMed |
| 39934538 | A review on NLRP3 inflammasome modulation by animal venom proteins/peptides: mechanisms and therapeutic insights. | Inflammopharmacology | 2025 | https://conductscience.org/library/papers/39934538 | PubMed |
| 39929578 | Biological and therapeutic significance of targeting NLRP3 inflammasome in the brain and the current efforts to develop brain-penetrant inhibitors. | Adv Pharmacol | 2025 | https://conductscience.org/library/papers/39929578 | PubMed |
| 39875780 | Research Progress in the Molecular Mechanism of NLRP3 Inflammasome in Alzheimer's Disease and Regulation by Natural Plant Products. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/39875780 | PubMed |
| 39690733 | Microglial Mayhem NLRP3 Inflammasome's Role in Multiple Sclerosis Pathology. | CNS Neurosci Ther | 2024 | https://conductscience.org/library/papers/39690733 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33972740
GET https://conductscience.org/api/papers/v1/33972740/references?page=2